Celyad Oncology SA (CLYYF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.1 Million EUR | 51.22% |
| 2022 | -12.19 Million EUR | 55.49% |
| 2021 | -27.38 Million EUR | -101.43% |
| 2020 | -13.59 Million EUR | 61.13% |
| 2019 | -34.97 Million EUR | 10.08% |
| 2018 | -38.89 Million EUR | -78.35% |
| 2017 | -21.8 Million EUR | 53.48% |
| 2016 | -46.87 Million EUR | 52.89% |
| 2015 | -99.5 Million EUR | -265.54% |
| 2014 | -27.22 Million EUR | -43.63% |
| 2013 | -18.95 Million EUR | -2518.97% |
| 2012 | -723.63 Thousand EUR | -722.45% |
| 2011 | 116.25 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.07 Million EUR | 0.0% |
| 2023 Q4 | -6.1 Million EUR | 0.0% |
| 2023 Q2 | -4.44 Million EUR | 0.0% |
| 2022 Q3 | - USD | N/A |
| 2022 FY | -12.19 Million EUR | 55.49% |
| 2022 Q1 | -18.11 Million EUR | 33.85% |
| 2022 Q2 | -12.22 Million EUR | 32.54% |
| 2022 Q4 | 4.44 Million EUR | 0.0% |
| 2021 Q1 | -8.73 Million EUR | 35.76% |
| 2021 FY | -27.38 Million EUR | -101.43% |
| 2021 Q4 | -27.38 Million EUR | -747.6% |
| 2021 Q3 | -3.23 Million EUR | 63.84% |
| 2021 Q2 | -8.93 Million EUR | -2.31% |
| 2020 FY | -13.59 Million EUR | 61.13% |
| 2020 Q4 | -13.59 Million EUR | 0.0% |
| 2020 Q2 | -22.98 Million EUR | 0.0% |
| 2019 Q4 | -34.97 Million EUR | 0.0% |
| 2019 FY | -34.97 Million EUR | 10.08% |
| 2019 Q2 | -28.73 Million EUR | 0.0% |
| 2018 Q2 | -61.08 Million EUR | 0.0% |
| 2018 Q4 | -38.89 Million EUR | 0.0% |
| 2018 FY | -38.89 Million EUR | -78.35% |
| 2017 Q4 | -21.8 Million EUR | 0.0% |
| 2017 Q2 | -22.25 Million EUR | 0.0% |
| 2017 FY | -21.8 Million EUR | 53.48% |
| 2016 Q4 | -46.87 Million EUR | 0.0% |
| 2016 FY | -46.87 Million EUR | 52.89% |
| 2016 Q2 | -51.95 Million EUR | 0.0% |
| 2015 Q4 | -99.5 Million EUR | 0.0% |
| 2015 FY | -99.5 Million EUR | -265.54% |
| 2015 Q2 | -115.61 Million EUR | 0.0% |
| 2014 Q4 | -27.22 Million EUR | 0.0% |
| 2014 FY | -27.22 Million EUR | -43.63% |
| 2014 Q2 | -34.75 Million EUR | 0.0% |
| 2013 FY | -18.95 Million EUR | -3884.43% |
| 2013 Q4 | -18.95 Million EUR | 0.0% |
| 2013 Q2 | -3.77 Million EUR | 0.0% |
| 2012 FY | -475.64 Thousand EUR | -509.13% |
| 2012 Q4 | -723.63 Thousand EUR | 0.0% |
| 2011 FY | 116.25 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 628.116% |
| CSL Limited | 10.52 Billion USD | 100.058% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 138.711% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 248.178% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1618.481% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 114.259% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 3.212% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 758.12% |
| Mesoblast Limited | 55.85 Million USD | 110.924% |
| Marizyme, Inc. | 18.56 Million USD | 132.861% |
| Genus plc | 190.6 Million USD | 103.201% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 372.919% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 602.682% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 997.353% |
| ContraFect Corporation | -6.02 Million USD | -1.261% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4632.119% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 179.551% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 210.907% |
| MultiCell Technologies, Inc. | 90.04 USD | 6777088.005% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -731.36% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 147.134% |
| EV Biologics, Inc. | 1.36 Million USD | 546.062% |
| Q BioMed Inc. | 4.06 Million USD | 250.295% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 119.971% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 705.528% |
| Biomind Labs Inc. | 711.4 Thousand USD | 957.743% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 147.647% |
| Skye Bioscience, Inc. | -5.72 Million USD | -6.652% |
| SQZ Biotechnologies Company | -36.23 Million USD | 83.161% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4464.682% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 208.031% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 372.139% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 30814.25% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1080.455% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 105.557% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 809.336% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 377.114% |
| GB Sciences, Inc. | 1.74 Million USD | 449.221% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3220.13% |
| argenx SE | -2.02 Billion USD | 99.699% |
| HST Global, Inc. | 96.79 Thousand USD | 6404.175% |
| Halberd Corporation | 144.72 Thousand USD | 4316.389% |
| Enzolytics Inc. | 981.65 Thousand USD | 721.603% |
| Resverlogix Corp. | 6.45 Million USD | 194.59% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -806.567% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 114.049% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 110.078% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.02% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 405.193% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 186.296% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1796.367% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 325.281% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 30.972% |
| AVAX Technologies, Inc. | -5.9 Million USD | -3.368% |
| ONE Bio Corp. | 9.04 Million USD | 167.5% |
| Zenith Capital Corp. | 10.06 Thousand USD | 60731.955% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.425% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3144.424% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 355.738% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3809.22% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -33211.497% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 3059.019% |
| Agentix Corp. | 37.63 Thousand USD | 16315.354% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -2310.886% |
| Helix BioMedix, Inc. | -2.57 Million USD | -137.429% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 130.095% |
| BioStem Technologies, Inc. | 4.47 Million USD | 236.449% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3131.989% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -465701.527% |
| LadRx Corporation | -2.03 Million USD | -199.636% |
| Cell Source, Inc. | 9.23 Million USD | 166.096% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -29800.039% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1060.692% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1060.692% |
| NovAccess Global Inc. | 2.17 Million USD | 380.105% |
| Affymax, Inc. | -5.59 Million USD | -9.023% |
| Itoco Inc. | 228.3 Thousand USD | 2772.74% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4587.128% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 223.099% |
| CytoDyn Inc. | 20.26 Million USD | 130.115% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -943022.102% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -65737.032% |
| Qrons Inc. | 351.42 Thousand USD | 1836.349% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 179.185% |
| SYBLEU INC | 473.71 Thousand USD | 1388.119% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2344.516% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2100.656% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 236.908% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1360.14% |
| International Stem Cell Corporation | 2.59 Million USD | 335.598% |
| Bioxytran, Inc. | 1.89 Million USD | 421.342% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9876.809% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 379.793% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 277.694% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 171.343% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 889.794% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -388.16% |
| Neutra Corp. | 52.18 Thousand USD | 11792.567% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -145.159% |
| PureTech Health plc | -167.19 Million USD | 96.35% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2391.548% |
| IXICO plc | -4.44 Million USD | -37.291% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 146.161% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 111.125% |
| CSL Limited | 10.52 Billion USD | 100.058% |
| Cellectis S.A. | -43.81 Million USD | 86.074% |